pegylated recombinant human arginase i bct 100

Drug Overview

pegylated recombinant human arginase i bct 100 is an innovative, investigational biological treatment. It belongs to a specialized group of medicines known as Targeted Therapy. Unlike traditional chemotherapy that attacks all fast-growing cells, BCT-100 is designed to “starve” specific cancer cells by removing a nutrient they need to survive.

The drug is a modified version of a human enzyme (arginase I) that has been treated with a process called “pegylation.” This process adds a protective coating to the enzyme, allowing it to stay in the patient’s body longer and work more effectively against the tumor.

• Generic Name: Pegylated recombinant human arginase I (BCT-100)
• US Brand Names: None (Currently an investigational drug)
• Drug Class: Arginine-depleting enzyme; Antineoplastic (Targeted Therapy)
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Not FDA Approved (Available only through clinical trials)
  
  Get details on pegylated recombinant human arginase i bct 100. Choose our hospital for innovative metabolic-based cancer treatments and guidance.

What Is It and How Does It Work? (Mechanism of Action)

BCT-100 works through a process called “Metabolic Starvation.” To understand this at the molecular level, we must look at a specific amino acid called arginine.

• Arginine Dependency: Most healthy cells in the body can create their own arginine to grow and repair themselves. However, many types of cancer cells—including certain liver and prostate cancers—lack a specific enzyme called argininosuccinate synthetase (ASS). Without this enzyme, these cancer cells are “arginine-auxotrophic,” meaning they cannot make their own arginine and must steal it from the patient’s bloodstream to survive.
• The Enzymatic Attack: BCT-100 is a recombinant human enzyme that circulates in the blood and breaks down arginine into two other substances: urea and ornithine.
• The Starvation Phase: Once BCT-100 is infused, the level of arginine in the blood drops to nearly zero. Healthy cells are unaffected because they can simply manufacture their own internal supply.
• Cell Cycle Arrest: The cancer cells, however, find their food source cut off. At the molecular level, this triggers a “starvation signal” that stops the cell’s division cycle (G1-phase arrest). Without arginine, the cancer cell cannot build proteins or copy its DNA, eventually leading to programmed cell death, known as apoptosis.

FDA-Approved Clinical Indications

As of early 2026, BCT-100 has not received full FDA approval. It is currently being studied for its effectiveness in cancers that are “arginine-hungry.”

Oncological Uses (Investigational):

• Hepatocellular Carcinoma (HCC): Advanced liver cancer.
• Arginine-auxotrophic Solid Tumors: Including specific types of prostate and lung cancer.
• Acute Myeloid Leukemia (AML): Certain blood cancers that lack the ability to produce arginine.
• Melanoma: Advanced skin cancers.

Non-oncological Uses:

• None.

Dosage and Administration Protocols

Because BCT-100 is an experimental drug, the dosage is determined by clinical trial protocols. It is usually administered based on the patient’s body weight.

• 
  Dose Adjustments: Physicians monitor liver function (ALT/AST levels) and kidney function (Creatinine) closely. If these levels become significantly abnormal, the dose is typically paused or reduced.

Clinical Efficacy and Research Results

Clinical data from recent studies (2020–2025) have shown promising results, particularly for patients who have not responded to standard therapies.

• Liver Cancer (HCC) Trials: In Phase 2 studies, BCT-100 has demonstrated a “Disease Control Rate” (the percentage of patients whose cancer shrank or stayed stable) of approximately 25% to 30% in patients with advanced liver cancer.
• Numerical Data: Research published in 2023 indicated that patients who achieved complete arginine depletion for more than 4 weeks had significantly longer “Progression-Free Survival” than those who did not.
• Pediatric AML: Recent small-scale trials in children with relapsed leukemia have shown that BCT-100 can reduce the number of cancer cells in the bone marrow when combined with other treatments.

Safety Profile and Side Effects

BCT-100 is generally better tolerated than traditional chemotherapy, but it does have specific side effects related to the body’s metabolic changes.

Black Box Warning

• There is no official Black Box Warning for BCT-100, as it is not yet an approved commercial product.

Common Side Effects (>10%)

• Fatigue: General feeling of tiredness.
• Nausea: Mild upset stomach.
• Abdominal Pain: Discomfort in the stomach area.
• Decreased Appetite: Loss of interest in food.

Serious Adverse Events

• Liver Enzyme Elevation: Temporary spikes in liver blood tests.
• Hypersensitivity: Rare allergic-like reactions during the infusion.
• Electrolyte Imbalance: Changes in the body’s salt and mineral levels.

Management Strategies

• For Infusion Reactions: Patients may be given an antihistamine before the infusion to prevent allergies.
• For Liver Health: Doctors perform weekly blood tests to ensure the liver is processing the drug safely.

Research Areas

In the fields of Immunotherapy and regenerative medicine, BCT-100 is being studied for its ability to change the “Tumor Microenvironment.” Recent research is looking at whether BCT-100 can be used alongside “Checkpoint Inhibitors” (another type of immunotherapy). Scientists believe that starving the cancer of arginine may make the tumor more visible to the body’s natural immune T-cells, allowing the immune system to regenerate a stronger defense against the cancer.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• ASS Protein Testing: A biopsy may be tested to see if the tumor lacks the ASS enzyme (confirming it is “arginine-hungry”).
• Liver and Kidney Panels: To ensure your organs are strong enough for treatment.
• Baseline Arginine Levels: To measure your starting blood nutrient levels.

Precautions During Treatment

• Monitor Fatigue: Patients should plan for rest on the day of and the day after the infusion.
• Dietary Consistency: Maintain a healthy, balanced diet; do not take extra arginine supplements as they will fight against the medicine.

“Do’s and Don’ts” List

• DO keep all weekly blood test appointments; these are vital for your safety.
• DO report any yellowing of the skin or eyes (jaundice) immediately.
• DON’T take any new herbal supplements or protein powders without checking with your oncologist first.
• DON’T ignore new or worsening stomach pain.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. BCT-100 is an investigational drug and is not yet available for general use outside of clinical trials. Always consult with your oncologist or a qualified healthcare provider regarding your specific medical condition and treatment options.